AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05027334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes
Description: Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
Study NCT01568372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
Study NCT03609099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg / day once a day oral treatment during 3 days.
Study NCT03609099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once a day oral treatment during 3 days.
Study NCT02726880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: 6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
Study NCT02726880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for care
Description: Referral for mental health issues and family support services
Study NCT02401945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study NCT03481634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection
Study NCT00572611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-bilastine
Description: Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
Study NCT01969617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg, then placebo
Description: One single oral dose Nalmefene on Day 1 and Placebo on Day 8
Study NCT01969617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then Nalmefene 18 mg
Description: One single oral dose Placebo on Day 1 and Nalmefene on Day 8
Study NCT00246506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
Study NCT00246506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
Study NCT04239794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
Study NCT04239794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
Study NCT03048838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction behavioral intervention
Study NCT03048838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Promotion Intervention
Study NCT02845778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each sachet contains 0.5 g
Study NCT02410954 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NeuroConn Direct Current stimulator Multiple Channel -4
Description: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
Study NCT02410954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn Direct Current stimulator Multiple Channel -4
Description: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
Study NCT01887119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study NCT01887119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplerenone-matched placebo
Study NCT03400657 — intervention group
Intervention type: PROCEDURE
Intervention: Multi-disciplinary Treatment
Description: due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
Study NCT03778320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Single oral dose
Study NCT03778320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Serine
Description: Single oral dose
Study NCT00600691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: one tablet (5mg) of finasteride
Study NCT04798534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service decentralization facilitation intervention
Description: The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
Study NCT00042926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00042926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00042926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography
Study NCT00042926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Study NCT00042926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Study NCT02350387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Short Duration Exercise
Description: Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
Study NCT02350387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intensity Long Duration Exercise
Description: Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
Study NCT02061046 — intervention group
Intervention type: DEVICE
Intervention: CPAP therapy
Description: 8 weeks of CPAP therapy
Study NCT03728491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulator
Description: US Mentor simulator, lung module, provided by 3D Healthcare Systems
Study NCT03728491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy figurants
Description: Medical students or volunteers without any pathology in thorax
Study NCT01976897 — intervention group
Intervention type: OTHER
Intervention: Knee flexion measurement 1
Description: The angle of knee flexion during resting, supine position is measured by a first person.
Study NCT01976897 — intervention group
Intervention type: OTHER
Intervention: Knee flexion measurement 2
Description: The angle of knee flexion during resting, supine position is measured by a second person.
Study NCT01976897 — intervention group
Intervention type: OTHER
Intervention: Heel - interface pressure measurements
Description: The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media.
Study NCT04451824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CL-100
Description: Red Light LED device for circumferential reduction
Study NCT02607540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 cycles cisplatin-5-fluorouracil
Description: 2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
Study NCT02607540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 cycles cisplatin-5-fluorouracil
Description: 4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
Study NCT02607540 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study NCT02607540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study NCT00042926 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc 99m sulfur colloid
Study NCT04642924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence-guided surgery
Study NCT02761577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
Study NCT02761577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
Study NCT02452398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
Study NCT02452398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
Study NCT02452398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
Study NCT01705158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and liposomal doxorubicin
Description: Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Study NCT03481634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study NCT00627003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
Study NCT00627003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets administered daily for 5 weeks
Study NCT04216017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kenalog
Description: Cortisone injection into shoulder
Study NCT04216017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection into shoulder
Study NCT00510133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRNVAC1
Description: Autologous dendritic cell vaccine
Study NCT01119131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 at 10,000 IU a day
Study NCT01119131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: 1000mg calcium daily
Study NCT01119131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Description: 1000mg calcium daily
Study NCT01119131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
Study NCT04170257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic examination using white light, NBI and iodine staining
Description: Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
Study NCT01529840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
Study NCT05283057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: single dose of the SGLT inhibitor Empagliflozin was given
Study NCT05283057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo that is similar to Empagliflozin in physical appearance
Study NCT03533179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30.
Study NCT03533179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or >25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
Study NCT03533179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - glucagon dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
Study NCT03533179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - esmolol dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
Study NCT02414334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Study NCT02414334 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Study NCT04264598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study NCT03875807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR done at 0 degrees KFA
Description: Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
Study NCT03875807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR done at 30 degrees KFA
Description: Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Study NCT05266300 — intervention group
Intervention type: GENETIC
Intervention: DPYD genotype
Description: The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G>A) rs67376798(c.2846A>T) rs55886062(c.1679T>G) rs56038477(75017182)/(c.1236G>A)
Study NCT02502019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows
Description: HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
Study NCT03413826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
Study NCT01472406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sansum Closed-Loop Artificial Pancreas
Description: The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
Study NCT01472406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin infusion pump
Description: The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
Study NCT01472406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: The CGM, which is an approved device (P050012), measures interstitial glucose.
Study NCT01472406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zone-Model Predictive Control algorithm
Description: The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
Study NCT01472406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safety Health Monitoring System
Description: The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
Study NCT02759575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
Study NCT02759575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70 Gy in 35 fractions over 7 weeks
Study NCT02759575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week